Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge